Data suggest that women with the CYP2D6 poor metaboliser phenotype have worse breast cancer outcomes, and may have different tamoxifen-related toxicity profiles compared with women with a normal CYP2D6 activity (Goetz et al, 2005; Desta and Flockhart, 2007). The gene discussed is CYP2D6; the disease is breast cancer.